tiprankstipranks
Trending News
More News >

Poseida Therapeutics downgraded to Neutral from Buy at BTIG

BTIG analyst Justin Zelin downgraded Poseida Therapeutics (PSTX) to Neutral from Buy after Roche (RHHBY) agreed to acquire Poseida for $13 per share in cash, comprised of $9 per share in cash at closing and a non-tradeable contingent value right, or CVR, to receive up to $4 per share in cash upon achievement of specific milestones. The firm views the deal terms as “very favorable to both Poseida shareholders and Roche,” the analyst tells investors.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue